Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.
about
Epigenomics of clear cell renal cell carcinoma: mechanisms and potential use in molecular pathologyGenetic and Chromosomal Aberrations and Their Clinical Significance in Renal NeoplasmsAdverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research networkIntegrated molecular analysis of clear-cell renal cell carcinoma.Medical treatment of renal cancer: new horizonsAlterations of Epigenetic Regulators in Pancreatic Cancer and Their Clinical ImplicationsSETD2: an epigenetic modifier with tumor suppressor functionalityThe roles of chromatin-remodelers and epigenetic modifiers in kidney cancerComprehensive review of BAP1 tumor predisposition syndrome with report of two new casesRenal cell carcinoma.The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma.Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations.The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma.Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNAIntratumoral heterogeneity analysis reveals hidden associations between protein expression losses and patient survival in clear cell renal cell carcinoma.Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell CarcinomaTumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapyImpact of recurrent copy number alterations and cancer gene mutations on the predictive accuracy of prognostic models in clear cell renal cell carcinoma.Mutation and expression analysis in medulloblastoma yields prognostic variants and a putative mechanism of disease for i17q tumors.A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma.Simultaneous isolation of high-quality DNA, RNA, miRNA and proteins from tissues for genomic applications.VHL, the story of a tumour suppressor gene.Renal cell carcinoma: molecular biology and targeted therapyClinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.Radiogenomics of clear cell renal cell carcinoma: preliminary findings of The Cancer Genome Atlas-Renal Cell Carcinoma (TCGA-RCC) Imaging Research GroupTCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtypeIdentifying molecular genetic features and oncogenic pathways of clear cell renal cell carcinoma through the anatomical (PADUA) scoring systemValidation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma.Suppression of Enhancer Overactivation by a RACK7-Histone Demethylase ComplexWhat a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma.Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas.Clear Cell Renal Cell Carcinoma: Associations Between CT Features and Patient Survival.Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets.Histone modifications: implications in renal cell carcinoma.Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defectsPrognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitors.Cooperation and antagonism among cancer genes: the renal cancer paradigmPBRM1 and BAP1 as novel targets for renal cell carcinomaManagement of metastatic kidney cancer in the era of personalized medicine.
P2860
Q26752925-62326F23-E6FA-49B5-B5AF-DD8EF9AA7E13Q26785930-2A5725F0-E051-49A7-8461-0EF9CB769833Q27852242-04B38E2C-0C89-4DA0-8563-13BAAA00BDFFQ27852382-951FB880-1F9C-4906-AC0A-6A5F54FB2EE6Q28073174-9F01DAFC-C9BE-4290-9F8C-85B90AC0DEDBQ28074465-6C52B6C4-0222-4A41-AFFA-5804A94041E2Q28075731-671CD128-0F33-4F6A-A2A1-D822CC367D01Q28083152-4A574D02-660E-42D7-BBCE-6FCFFDB29356Q28397229-269ADD97-6583-4CE5-A18A-C37F4AABC75EQ30235364-8E4D3BC9-93C8-4678-B903-A6BE61FDAC2CQ30277177-82CB9115-979E-4385-BADE-D8144A300C4FQ33570946-5B26FBC3-BCE7-4F74-A3D4-B908B004F811Q33683959-715A9507-7649-46C4-AFFA-466BA7B875B8Q33709786-E1ACDAD6-A074-45FC-B678-76444723141BQ33913967-DB6E9F83-3B2D-44D9-B8AA-445C19F7F814Q33947929-967A7A5C-D412-4192-B279-A238B27BD78BQ34074997-9E63852A-4CAC-4D24-AA26-CC9EFB967C0BQ34098513-BBE15A44-6421-4EA9-A477-04244B88209BQ34108929-63A252B4-EAD7-4AD4-A6A6-44D5B6B082C8Q34413144-EAE84950-82DB-4A03-9201-05941D92B092Q34414411-2F7E83DC-F1A7-4923-B5E0-DDF2152277DDQ34455226-036763A8-CC54-4797-A64B-8370A22B9009Q34513914-0443C0A2-6BDF-4584-BF79-902FCAAE96E3Q35129478-1A3FA771-ED45-46FC-A767-767666FD91B4Q35574106-E2F6F9DA-BE82-40F9-8EAE-18EE2CA84A5DQ35667690-06306E7B-9442-4050-ACCE-D9047C741623Q35915304-BDA9FD90-1EB1-4299-B867-4227BBD8A25AQ36716606-AAEAB094-28CE-4737-812E-53D9AF2E392AQ36783309-F19B52F5-0D37-4AA0-91C2-7FC7F41788FDQ36832167-8586DB2B-E07A-4E27-A5F3-9054226F7C47Q37016755-D6039586-874C-4DB4-8CF6-C5DD649DB56FQ37114357-53589882-0C2A-4340-9036-8E3D85C1F9C4Q37172780-F0E4EA30-9DA3-4AE5-A000-D37A5E443E91Q37330688-031612EE-C5B7-4FE9-A493-54F2E3FBD4F4Q37414110-96FA3A8D-6257-4940-9D27-8E3969CF459FQ37550216-E34711B2-C471-4273-BCF3-90F4E6CFC154Q38116001-41CF1765-E4BA-4CBA-9E38-12FA30F974E7Q38119888-30A3A764-8A95-4D36-B039-72964F1E7818Q38122565-DE8B0E2C-5672-43E0-98AD-A063114FC192Q38180744-CD484105-6E62-48DB-B099-C6BF62488AFC
P2860
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Clinical and pathologic impact ...... ear cell renal cell carcinoma.
@ast
Clinical and pathologic impact ...... ear cell renal cell carcinoma.
@en
type
label
Clinical and pathologic impact ...... ear cell renal cell carcinoma.
@ast
Clinical and pathologic impact ...... ear cell renal cell carcinoma.
@en
prefLabel
Clinical and pathologic impact ...... ear cell renal cell carcinoma.
@ast
Clinical and pathologic impact ...... ear cell renal cell carcinoma.
@en
P2093
P2860
P50
P1433
P1476
Clinical and pathologic impact ...... ear cell renal cell carcinoma.
@en
P2093
A Ari Hakimi
Adriana Heguy
Emily H Cheng
James J Hsieh
James Wren
Martin H Voss
Mithat Gonen
Paul Russo
Satish K Tickoo
P2860
P304
P356
10.1016/J.EURURO.2012.09.005
P407
P577
2012-09-27T00:00:00Z